Noteworthy, the expression of EZH2 in ovarian cancers has been shown to be regulated by different non-coding RNAs, for example miR-298 [198] and lncRNA HOTAIR (HOX transcript antisense RNA) [199], providing additional druggable epigenetic targets in EOC cells and TECs in order to suppress neoangiogenesis and ovarian tumor progression. Here, EZH2 is linked to ovarian carcinoma.